Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

GKL-006Allo Injection in Patients With Advanced Solid Tumors

14. juli 2026 oppdatert av: Beijing Gene Key Life Technology Co., Ltd

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.

The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.

Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.

Studietype

Intervensjonell

Registrering (Antatt)

27

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Cancer Hospital Chinese Academy of Medical Sciences
  • Telefonnummer: +86-316-5916013
  • E-post: lining@cisams.ac.cn

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Able to understand and voluntarily sign the informed consent form.
  • Aged 18 to 75 years.
  • Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
  • At least one measurable tumor lesion during screening according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
  • Adequate hematologic and organ function.
  • Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
  • Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.

Exclusion Criteria:

  • Recently received radical radiotherapy or other anti-tumor therapy.
  • Known hypersensitivity to any component of the study treatment.
  • Prior history or concurrent malignancy that has not been cured.
  • Active infection, known or suspected autoimmune disease.
  • Last anti-tumor treatment toxicity not yet recovered to suitable status.
  • Other organ dysfunction or situations deemed inappropriate by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte. GKL-006Allo is an allogeneic iNKT cell.
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
Andre navn:
  • Allogeneic iNKT Cell Therapy
  • Allogeneic invariant natural killer T cell therapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Dose-Limiting Toxicities (DLTs)
Tidsramme: From the first dose through the end of the DLT observation period, assessed up to 28 days.
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
From the first dose through the end of the DLT observation period, assessed up to 28 days.
Incidence and Severity of Adverse Events
Tidsramme: From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Overall Survival (OS)
Tidsramme: From the first dose of study treatment until death from any cause, assessed up to 18 months.
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
From the first dose of study treatment until death from any cause, assessed up to 18 months.
Change From Baseline in EORTC QLQ-C30 Scale Scores
Tidsramme: Baseline and scheduled post-baseline assessments, up to 18 months.
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores for each scale range from 0 to 100. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
Baseline and scheduled post-baseline assessments, up to 18 months.
Immunogenicity
Tidsramme: From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
Disease Control Rate (DCR)
Tidsramme: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective Response Rate (ORR)
Tidsramme: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
Tidsramme: From 60 minutes before the first dose through 150 days.
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
Tidsramme: From 60 minutes before the first dose through 150 days.
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
Tidsramme: From 60 minutes before the first dose through 150 days.
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of terminal elimination half-life (t½)
Tidsramme: From 60 minutes before the first dose through 150 days.
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of NK cells
Tidsramme: From 60 minutes before the first dose through 150 days.
Immune cell subsets
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
Tidsramme: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
Tidsramme: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ning Li, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. august 2026

Primær fullføring (Antatt)

30. september 2028

Studiet fullført (Antatt)

31. januar 2029

Datoer for studieregistrering

Først innsendt

9. juli 2026

Først innsendt som oppfylte QC-kriteriene

14. juli 2026

Først lagt ut (Faktiske)

15. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

15. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. juli 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • GKL006ALLOST01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere